JP2019526274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526274A5 JP2019526274A5 JP2019524114A JP2019524114A JP2019526274A5 JP 2019526274 A5 JP2019526274 A5 JP 2019526274A5 JP 2019524114 A JP2019524114 A JP 2019524114A JP 2019524114 A JP2019524114 A JP 2019524114A JP 2019526274 A5 JP2019526274 A5 JP 2019526274A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- protein
- fusion protein
- msp3
- antigenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022085159A JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16180544 | 2016-07-21 | ||
| EP16180544.5 | 2016-07-21 | ||
| PCT/SG2017/050369 WO2018017020A1 (en) | 2016-07-21 | 2017-07-21 | Biofusion proteins as anti-malaria vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022085159A Division JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019526274A JP2019526274A (ja) | 2019-09-19 |
| JP2019526274A5 true JP2019526274A5 (enExample) | 2020-08-27 |
Family
ID=56550732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524114A Pending JP2019526274A (ja) | 2016-07-21 | 2017-07-21 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
| JP2022085159A Active JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022085159A Active JP7579298B2 (ja) | 2016-07-21 | 2022-05-25 | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210038706A1 (enExample) |
| EP (2) | EP3487526B1 (enExample) |
| JP (2) | JP2019526274A (enExample) |
| KR (2) | KR20240154691A (enExample) |
| CN (1) | CN109963586B (enExample) |
| AU (1) | AU2017300965B2 (enExample) |
| BR (1) | BR112019001115A2 (enExample) |
| CA (1) | CA3031399A1 (enExample) |
| TW (1) | TWI780058B (enExample) |
| WO (1) | WO2018017020A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021531345A (ja) | 2018-07-16 | 2021-11-18 | ディーシープライム・ベスローテン・フェンノートシャップDcprime B.V. | 腫瘍ワクチン接種に用いるための組合せ製品 |
| WO2020033398A1 (en) * | 2018-08-06 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating atii cell-dependent lung diseases |
| EP3883600B1 (en) * | 2018-11-23 | 2025-03-12 | Strike Pharma AB | Bi-specific conjugates |
| WO2020217226A1 (en) | 2019-04-25 | 2020-10-29 | Dcprime B.V. | Methods of tumor vaccination |
| NL2023863B1 (en) * | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
| CN111135290A (zh) * | 2020-01-16 | 2020-05-12 | 定山石生物科技(北京)有限公司 | 一种用于激活人体免疫细胞的多肽试剂 |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| JP2023531537A (ja) | 2020-06-30 | 2023-07-24 | メンドゥス・ベスローテン・フェンノートシャップ | 卵巣癌ワクチンでの白血病由来細胞の使用 |
| EP4281102A1 (en) | 2021-01-22 | 2023-11-29 | Mendus B.V. | Methods of tumor vaccination |
| BE1029148B1 (fr) * | 2021-02-26 | 2022-09-26 | Curavac Europe | Vaccin pour un traitement therapeutique ou prophylactique de la myastenie grave |
| CN118207228B (zh) * | 2024-03-21 | 2025-03-14 | 中国科学院上海免疫与感染研究所 | 一种防治结合的多时期双靶点串联疟疾mRNA疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3158900A (en) * | 1999-02-25 | 2000-09-14 | Smithkline Beecham Biologicals (Sa) | Immunogens comprising a peptide and a carrier derived from h.influenzae protein |
| DK200201741A (da) * | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| US20050112133A1 (en) * | 2003-10-24 | 2005-05-26 | Pierre Druilhe | GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it |
| UA84728C2 (ru) * | 2003-12-17 | 2008-11-25 | Вайет | ПРОЦЕСС ОБРАЗОВАНИЯ ИММУНОГЕННОГО КОНЪЮГАТА, ИММУНОГЕННЫЙ КОНЪЮГАТ БЕЛКА Aβ С БЕЛКОМ-НОСИТЕЛЕМ И ИММУНОЛОГИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ |
| WO2012163289A1 (zh) * | 2011-06-01 | 2012-12-06 | 厦门大学 | 包含白喉毒素无毒突变体crm197或其片段的融合蛋白 |
| US9802987B2 (en) * | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
-
2017
- 2017-07-21 KR KR1020247034516A patent/KR20240154691A/ko active Pending
- 2017-07-21 CN CN201780051251.4A patent/CN109963586B/zh active Active
- 2017-07-21 KR KR1020197005103A patent/KR20190090775A/ko not_active Ceased
- 2017-07-21 TW TW106124623A patent/TWI780058B/zh active
- 2017-07-21 US US16/319,078 patent/US20210038706A1/en not_active Abandoned
- 2017-07-21 JP JP2019524114A patent/JP2019526274A/ja active Pending
- 2017-07-21 CA CA3031399A patent/CA3031399A1/en not_active Abandoned
- 2017-07-21 BR BR112019001115A patent/BR112019001115A2/pt unknown
- 2017-07-21 EP EP17746213.2A patent/EP3487526B1/en active Active
- 2017-07-21 EP EP22182920.3A patent/EP4147715A1/en active Pending
- 2017-07-21 WO PCT/SG2017/050369 patent/WO2018017020A1/en not_active Ceased
- 2017-07-21 AU AU2017300965A patent/AU2017300965B2/en active Active
-
2022
- 2022-05-25 JP JP2022085159A patent/JP7579298B2/ja active Active
- 2022-07-06 US US17/858,642 patent/US20220409712A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526274A5 (enExample) | ||
| Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
| US11771755B2 (en) | Self-asssembling nanostructure vaccines | |
| Stover et al. | Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. | |
| JP2023524054A (ja) | ベータコロナウイルスの予防と治療 | |
| CN105792842A (zh) | 埃巴病毒疫苗 | |
| JP2015509707A5 (enExample) | ||
| CN115850506B (zh) | 一种cd4辅助性t细胞表位融合肽及其疫苗 | |
| CN113301918B (zh) | Cmv的通过融合修饰的病毒样颗粒 | |
| US8580274B2 (en) | Drug transporter, and adjuvant and vaccine each utilizing same | |
| ES2236718T3 (es) | Proteina portadora de efecto adyuvante, complejo inmunogenico que la contiene, su procedimiento de preparacion, secuencia nucleotidica y vacuna. | |
| Haeuw et al. | The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides | |
| JPH10509325A (ja) | 粘膜免疫を刺激する免疫原 | |
| Shivachandra et al. | Immunogenicity of recombinant Omp16 protein of Pasteurella multocida B: 2 in mouse model | |
| EP4415753A1 (en) | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing | |
| WO2019228032A1 (zh) | 磷酸化多肽抗原疫苗及其制备方法和应用 | |
| TWI683668B (zh) | 用於免疫作用中有效抗體生産的新穎蛋白質結構 | |
| Ohtake et al. | Recombinant therapeutic protein vaccines | |
| CN113801206A (zh) | 利用受体识别域诱导抗新冠病毒中和抗体的方法 | |
| JP2000000099A (ja) | ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体 | |
| CN106337038B (zh) | 一种通过转肽酶剪切制备疫苗的方法及其应用 | |
| US11535651B2 (en) | Hepatitis B nanoparticle-based vaccine for influenza virus | |
| CN116813793B (zh) | 融合蛋白以及其应用 | |
| JP6590916B2 (ja) | 毒素原性大腸菌およびジェジュニ菌の組合せの組換えコンストラクト | |
| Montaner et al. | Ganglioside GM1-binding peptides as adjuvants of antigens inoculated by the intranasal route |